Loading...
•
Mar 31, 2021
Omeros Q1 2021 Earnings Report
Omeros reported a net loss for Q1 2021, but saw increased OMIDRIA revenues.
Key Takeaways
Omeros Corporation reported first quarter 2021 financial results, with OMIDRIA revenues at $21.1 million. The company's net loss was $35.1 million, or $0.57 per share. As of March 31, 2021, Omeros had $100.5 million in cash, cash equivalents and short-term investments.
OMIDRIA revenues for Q1 2021 were $21.1 million.
Net loss in Q1 2021 was $35.1 million, or $0.57 per share.
Omeros had cash, cash equivalents and short-term investments of $100.5 million as of March 31, 2021.
Dosing of patients with narsoplimab in the I-SPY COVID-19 platform trial began in March 2021.
Forward Guidance
Omeros is progressing toward the anticipated launch of narsoplimab for TA-TMA and building momentum with OMIDRIA following CMS' confirmation of separate payment for OMIDRIA in the ASC setting.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...